Evidence map›Paper›PMID 37200996›Full record

ArticleEClinicalMedicine2023

Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database.

Weiqi Liao, Carol A C Coupland, Hamish Innes, Peter Jepsen, Philippa C Matthews, Cori Campbell, DeLIVER consortium, Eleanor Barnes, Julia Hippisley-Cox

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Steroids fromMolecular biology research communications · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. A Patient Charter to Improve Care for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Weiqi LiaoNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Carol A C CouplandNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Hamish InnesSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Peter JepsenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Philippa C MatthewsThe Francis Crick Institute, London, UK.
Cori CampbellNuffield Department of Medicine, University of Oxford, Oxford, UK.
DeLIVER consortium
Eleanor BarnesNuffield Department of Medicine, University of Oxford, Oxford, UK.
Julia Hippisley-CoxNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
University of Oxford · GBUniversity College London Hospitals NHS Foundation Trust · GBGlasgow Caledonian University · GBAarhus University Hospital · DKUniversity of Nottingham · GB

Funding

Cancer Research UK 23390Cancer Research UK 29725Cancer Research UK DRCRPG-NOV22/100007Medical Research Council MR/K01532X/1Medical Research Council MR/P011462/1Medical Research Council MR/R023026/1Wellcome Trust
6 · The paper itself

Abstract

Background: Liver cancer has one of the fastest rising incidence and mortality rates among all cancers in the UK, but it receives little attention. This study aims to understand the disparities in epidemiology and clinical pathways of primary liver cancer and identify the gaps for early detection and diagnosis of liver cancer in England. Methods: This study used a dynamic English primary care cohort of 8.52 million individuals aged ≥25 years in the QResearch database during 2008-2018, followed up to June 2021. The crude and age-standardised incidence rates, and the observed survival duration were calculated by sex and three liver cancer subtypes, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (CCA), and other specified/unspecified primary liver cancer. Regression models were used to investigate factors associated with an incident diagnosis of liver cancer, emergency presentation, late stage at diagnosis, receiving treatments, and survival duration after diagnosis by subtype. Findings: 7331 patients were diagnosed with primary liver cancer during follow-up. The age-standardised incidence rates increased over the study period, particularly for HCC in men (increased by 60%). Age, sex, socioeconomic deprivation, ethnicity, and geographical regions were all significantly associated with liver cancer incidence in the English primary care population. People aged ≥80 years were more likely to be diagnosed through emergency presentation and in late stages, less likely to receive treatments and had poorer survival than those aged <60 years. Men had a higher risk of being diagnosed with liver cancer than women, with a hazard ratio (HR) of 3.9 (95% confidence interval 3.6-4.2) for HCC, 1.2 (1.1-1.3) for CCA, and 1.7 (1.5-2.0) for other specified/unspecified liver cancer. Compared with white British, Asians and Black Africans were more likely to be diagnosed with HCC. Patients with higher socioeconomic deprivation were more likely to be diagnosed through the emergency route. Survival rates were poor overall. Patients diagnosed with HCC had better survival rates (14.5% at 10-year survival, 13.1%-16.0%) compared to CCA (4.4%, 3.4%-5.6%) and other specified/unspecified liver cancer (12.5%, 10.1%-15.2%). For 62.7% of patients with missing/unknown stage in liver cancer, their survival outcomes were between those diagnosed in Stages III and IV. Interpretation: This study provides an overview of the current epidemiology and the disparities in clinical pathways of primary liver cancer in England between 2008 and 2018. A complex public health approach is needed to tackle the rapid increase in incidence and the poor survival of liver cancer. Further studies are urgently needed to address the gaps in early detection and diagnosis of liver cancer in England. Funding: The

Indexed as

CholangiocarcinomaDisparitiesEpidemiologyHepatocellular carcinoma (HCC)Liver cancer

Identifiers

PMID37200996
PMCPMC10186486
OpenAlexW4376126477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.